This study focuses on patients who need surgery for tricuspid regurgitation, a heart condition where one of the heart valves (the tricuspid valve) doesn’t close properly, causing blood to flow backward. The study examines the effectiveness of a medication called levosimendan (ZIMINO) compared to placebo in preventing complications after heart surgery.
The purpose of this research is to determine if giving levosimendan before surgery can help prevent a condition called low cardiac output syndrome, which occurs when the heart cannot pump enough blood to meet the body’s needs after surgery. During the study, patients will receive either levosimendan or placebo through an intravenous infusion before their tricuspid valve surgery.
The medication or placebo will be given as a single treatment before the surgery. After the operation, patients will be monitored for 90 days to check for signs of heart-related complications, including the need for additional medications to support heart function, the use of devices to help the heart pump blood, or the need for special treatments to support kidney function.



France